Clinical trial · Interventional
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients: a Randomized Controlled Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Oocyte vitrification after in vitro maturation (IVM) is one of the main techniques for preserving female fertility before chemotherapy for breast cancer. In this technique, originally developed for patients with ovarian pathology, polycystic ovarian syndrome, induction of an LH peak has been shown to improve outcomes. Young women with breast cancer, who are candidates for urgent fertility preservation, do not have ovarian pathology. The objective of the present study is to assess whether the absence of therapeutic intervention prior to oocyte retrieval for IVM in these patients is at least as effective as the injection of hCG or GnRH agonist used in routine practice.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Fertility Preservation | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GnRH a | Other | — | UNRESOLVED |
| hCG | Other | — | UNRESOLVED |
| No hormone | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Without injection group
- description
- no injection used as priming
- interventionNames
- Other: hCG
- Other: GnRH a
- type
- ACTIVE_COMPARATOR
- label
- hCG group
- description
- hCG used as priming
- interventionNames
- Other: No hormone
- Other: GnRH a
- type
- ACTIVE_COMPARATOR
- label
- GnRHa group
- description
- GnRH agonist used as priming
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 38 Years
Show eligibility criteria text
Inclusion Criteria: * age between 18 and 38 years; * diagnosis of breast cancer (BC) * indication for neoadjuvant chemotherapy; * body mass index (BMI) ≤27kg/m2; regular ovulatory cycles; * transvaginal ultrasound showing the presence of two ovaries with an antral follicle count (AFC) between 10 and 30 follicles; * affiliation to the national social security system. * Written informed consent was obtained from all participants Exclusion Criteria: * \- previous chemotherapy, ovarian surgery or endometrioma;
References
Publications (1)
- DERIVEDSonigo C, Le Conte G, Boubaya M, Ohanyan H, Presse M, El Hachem H, Cedrin-Durnerin I, Benoit A, Sifer C, Sermondade N, Grynberg M. Priming Before In Vitro Maturation Cycles in Cancer Patients Undergoing Urgent Fertility Preservation: a Randomized Controlled Study. Reprod Sci. 2020 Dec;27(12):2247-2256. doi: 10.1007/s43032-020-00244-0. Epub 2020 Jul 2. PMID 32617881